Prognostic molecular biomarkers for cutaneous malignant melanoma

Journal of Surgical Oncology

Volumn 104, Issue 4, 2011, Pages 438-446

  Tanaka, Ryo ^a   Koyanagi, Kazuo ^a   Narita, Norihiko ^a   Kuo, Christine ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

biomarkers; circulating tumor cells; epigenetics; lymph node; melanoma; microRNA

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; B RAF KINASE; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR4; DNA; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 7; GANGLIOSIDE GD2; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GLYCOPROTEIN GP 100; GSK 2118436; MELAN A; MELANOMA ANTIGEN 3; MELANOMA CHONDROITIN SULFATE PROTEOGLYCAN; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; PROTEOCHONDROITIN SULFATE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SURVIVIN; TRANSCRIPTION FACTOR PAX3; TRP 1 PROTEIN; TRP 2 PROTEIN; TUMOR MARKER; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VEMURAFENIB;

ADJUVANT THERAPY; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CANCER TISSUE; CELL ASSAY; CIRCULATING TUMOR CELL; DNA METHYLATION; EPIGENETICS; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CARCINOGENESIS;

EPIGENOMICS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052034187     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21969     Document Type: Review

References (95)

1. Takeuchi H, Kuo C, Morton DL, et al.: Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res 2003; 63: 441-448. (Pubitemid 36152505)
2. Kawakami Y, Eliyahu S, Delgado CH, et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3515-3519. (Pubitemid 24139460)
3. Glaser R, Rass K, Seiter S, et al.: Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study. J Clin Oncol 1997; 15: 2818-2825. (Pubitemid 27330008)
4. Jung FA, Buzaid AC, Ross MI, et al.: Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997; 15: 2826-2831. (Pubitemid 27330009)
5. Koyanagi K, Kuo C, Nakagawa T, et al.: Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: Relation to disease stage in melanoma patients. Clin Chem 2005; 51: 981-988. (Pubitemid 40740878)
6. Koyanagi K, Mori T, O'Day SJ, et al.: Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 2006; 66: 6111-6117.
7. Koyanagi K, O'Day SJ, Boasberg P, et al.: Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 2010; 16: 2402-2408.
8. Koyanagi K, O'Day SJ, Gonzalez R, et al.: Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: Outcome prediction in a multicenter trial. J Clin Oncol 2005; 23: 8057-8064. (Pubitemid 46657408)
9. Kuo CT, Bostick PJ, Irie RF, et al.: Assessment of messenger RNA of beta 1 → 4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma. Clin Cancer Res 1998; 4: 411-418. (Pubitemid 28122757)
10. Takeuchi H, Morton DL, Kuo C, et al.: Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004; 22: 2671-2680. (Pubitemid 41103755)
11. Takeuchi H, Taback B, Kuo C, et al.: Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy. Ann Surg Oncol 2004; 11: 152S-155S.
12. Takeuchi H, Wascher RA, Kuo C, et al.: Molecular diagnosis of micrometastasis in the sentinel lymph node. Cancer Treat Res 2005; 127: 221-252.
13. Gaugler B, Van den Eynde B, van der Bruggen P, et al.: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-930. (Pubitemid 24065650)
14. Miyashiro I, Kuo C, Huynh K, et al.: Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem 2001; 47: 505-512. (Pubitemid 32222466)
15. Tsuchida T, Saxton RE, Irie RF:, Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 1987; 78: 55-60. (Pubitemid 17009770)
16. Tsuchida T, Saxton RE, Morton DL, et al.: Gangliosides of human melanoma. J Natl Cancer Inst 1987; 78: 45-54. (Pubitemid 17009769)
17. Maschhoff KL, Baldwin HS:, Molecular determinants of neural crest migration. Am J Med Genet 2000; 97: 280-288. (Pubitemid 32463492)
18. Scholl FA, Kamarashev J, Murmann OV, et al.: PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 2001; 61: 823-826. (Pubitemid 32174385)
19. Koyanagi K, O'Day SJ, Gonzalez R, et al.: Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 2006; 12: 1137-1143. (Pubitemid 43342501)
20. Campoli MR, Chang CC, Kageshita T, et al.: Human high molecular weight-melanoma-associated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004; 24: 267-296. (Pubitemid 40052428)
21. Goto Y, Arigami T, Murali R, et al.: High molecular weight-melanoma- associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell Melanoma Res 2010; 23: 137-140.
22. Anthony TE, Mason HA, Gridley T, et al.: Brain lipid-binding protein is a direct target of Notch signaling in radial glial cells. Genes Dev 2005; 19: 1028-1033. (Pubitemid 40632448)
23. Arai Y, Funatsu N, Numayama-Tsuruta K, et al.: Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. J Neurosci 2005; 25: 9752-9761. (Pubitemid 41510915)
24. Haunerland NH, Spener F:, Fatty acid-binding proteins-Insights from genetic manipulations. Prog Lipid Res 2004; 43: 328-349. (Pubitemid 38952618)
25. Goto Y, Matsuzaki Y, Kurihara S, et al.: A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 2006; 66: 4443-4449.
26. Goto Y, Koyanagi K, Narita N, et al.: Aberrant fatty acid-binding protein 7 gene expression in cutaneous malignant melanoma. J Invest Dermatol 2010; 130: 221-229.
27. Takeuchi H, Morton DL, Elashoff D, et al.: Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005; 117: 1032-1038. (Pubitemid 41688581)
28. Zlotnik A, Yoshie O:, Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127. (Pubitemid 30398626)
29. Zlotnik A:, Chemokines and cancer. Int J Cancer 2006; 119: 2026-2029. (Pubitemid 44423657)
30. Monteagudo C, Martin JM, Jorda E, et al.: CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: Correlation with clinicopathological prognostic factors. J Clin Pathol 2007; 60: 596-599. (Pubitemid 46975211)
31. Navarini-Meury AA, Conrad C:, Melanoma and innate immunity-aActive inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol 2009; 19: 84-91.
32. Raman D, Baugher PJ, Thu YM, et al.: Role of chemokines in tumor growth. Cancer Lett 2007; 256: 137-165. (Pubitemid 47418345)
33. Richmond A, Yang J, Su Y:, The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009; 22: 175-186.
34. Takeuchi H, Kitago M, Hoon DS:, Effects of chemokines on tumor metastasis. Cancer Treat Res 2007; 135: 177-184.
35. Hoon DS, Kitago M, Kim J, et al.: Molecular mechanisms of metastasis. Cancer Metastasis Rev 2006; 25: 203-220. (Pubitemid 43886397)
36. Scala S, Ottaiano A, Ascierto PA, et al.: Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11: 1835-1841. (Pubitemid 40471847)
37. Takeuchi H, Fujimoto A, Tanaka M, et al.: CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004; 10: 2351-2358. (Pubitemid 38445693)
38. Kim J, Mori T, Chen SL, et al.: Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006; 244: 113-120. (Pubitemid 44297455)
39. Mora JR, Bono MR, Manjunath N, et al.: Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003; 424: 88-93. (Pubitemid 36834847)
40. Amersi FF, Terando AM, Goto Y, et al.: Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 2008; 14: 638-645. (Pubitemid 351231142)
41. Izraely S, Klein A, Sagi-Assif O, et al.: Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunol Lett 2010; 130: 107-114.
42. Chen SL, Iddings DM, Scheri RP, et al.: Lymphatic mapping and sentinel node analysis: Current concepts and applications. CA Cancer J Clin 2006; 56: 292-309; quiz 316-297. (Pubitemid 44527491)
43. Amersi F, Giuliano AE, Hoon DS:, Molecular assessment of sentinel lymph nodes. In:, Mariani G, Giuliano AE, Strauss HW, editors. Radioguided surgery. New York: Springer; 2008; pp 206-217.
44. Grimm EA, Hoon DS, Duncan LM:, Biomarkers for cutaneous melanoma. In:, Balch CM, Houghton AN, Sober AJ, et al. (editors). Cutaneous melanoma. St. Louis: Quality Medical Publishing, Inc.; 2008; pp 883-897.
45. Karim RZ, Scolyer RA, Li W, et al.: False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg 2008; 247: 1003-1010. (Pubitemid 351770421)
46. Kuo CT, Hoon DS, Takeuchi H, et al.: Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 2003; 21: 3566-3572. (Pubitemid 46594047)
47. Martinez SR, Mori T, Hoon DS:, Molecular upstaging of sentinel lymph nodes in melanoma: Where are we now ? Surg Oncol Clin N Am 2006; 15: 331-340.
48. Morton DL, Hoon DS, Cochran AJ, et al.: Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238: 538-549; discussion 549-550.
49. Bostick PJ, Morton DL, Turner RR, et al.: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17: 3238-3244. (Pubitemid 29470658)
50. Nicholl MB, Elashoff D, Takeuchi H, et al.: Molecular upstaging based on paraffin-embedded sentinel lymph nodes: Ten-year follow-up confirms prognostic utility in melanoma patients. Ann Surg 2011; 253: 116-122.
51. Mocellin S, Hoon DS, Pilati P, et al.: Sentinel lymph node molecular ultrastaging in patients with melanoma: A systematic review and meta-analysis of prognosis. J Clin Oncol 2007; 25: 1588-1595. (Pubitemid 46733087)
52. Hoon DS:, Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma ? Nat Clin Pract Oncol 2004; 1: 74-75. (Pubitemid 40823744)
53. Hoon DS, Bostick P, Kuo C, et al.: Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000; 60: 2253-2257. (Pubitemid 30225191)
54. Mocellin S, Hoon D, Ambrosi A, et al.: The prognostic value of circulating tumor cells in patients with melanoma: A systematic review and meta-analysis. Clin Cancer Res 2006; 12: 4605-4613. (Pubitemid 44297811)
55. Voit C, Kron M, Rademaker J, et al.: Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 2005; 23: 1218-1227. (Pubitemid 46202279)
56. Hoon DS, Wang Y, Dale PS, et al.: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13: 2109-2116.
57. Xi L, Nicastri DG, El-Hefnawy T, et al.: Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 2007; 53: 1206-1215. (Pubitemid 47020975)
58. de Graaf H, Maelandsmo GM, Ruud P, et al.: Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: Studies on the epithelial glycoprotein gene EGP-2. Int J Cancer 1997; 72: 191-196. (Pubitemid 27314658)
59. Kitago M, Koyanagi K, Nakamura T, et al.: mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem 2009; 55: 757-764.
60. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al.: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324.
61. Hoshimoto S, Shingai T, Wang H, et al.: Validation of a multimarker blood assay for postoperative assessment of stage IV melanoma patients in a prospective international phase III trial. J Clin Oncol 2009; 27: Abstract 9045.
62. Udayakumar D, Tsao H:, Melanoma genetics: An update on risk-associated genes. Hematol Oncol Clin North Am 2009; 23: 415-429, vii.
63. Wu C, Morris JR:, Genes, genetics, and epigenetics: A correspondence. Science 2001; 293: 1103-1105. (Pubitemid 32758084)
64. Shinozaki M, Fujimoto A, Morton DL, et al.: Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10: 1753-1757. (Pubitemid 38435567)
65. Flaherty KT, Puzanov I, Kim KB, et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
66. Kefford R, Arkenau H, Brown MP, et al.: Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28: Abstr 8503.
67. Iwamoto T, Taniguchi M, Asai N, et al.: cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 1993; 8: 1087-1091. (Pubitemid 23087445)
68. Takahashi M, Buma Y, Iwamoto T, et al.: Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988; 3: 571-578. (Pubitemid 19003664)
69. Zbuk KM, Eng C:, Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007; 7: 35-45. (Pubitemid 46020845)
70. Takahashi M:, The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001; 12: 361-373. (Pubitemid 32851748)
71. Kodama Y, Asai N, Kawai K, et al.: The RET proto-oncogene: A molecular therapeutic target in thyroid cancer. Cancer Sci 2005; 96: 143-148. (Pubitemid 40575914)
72. Wells SA, Jr., Santoro M:, Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009; 15: 7119-7123.
73. Sawai H, Okada Y, Kazanjian K, et al.: The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 2005; 65: 11536-11544. (Pubitemid 41821712)
74. Narita N, Tanemura A, Murali R, et al.: Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 2009; 28: 3058-3068.
75. Healy E, Belgaid C, Takata M, et al.: Prognostic significance of allelic losses in primary melanoma. Oncogene 1998; 16: 2213-2218. (Pubitemid 28220651)
76. Shirasaki F, Takata M, Hatta N, et al.: Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23. Cancer Res 2001; 61: 7422-7425. (Pubitemid 32995028)
77. Fujimoto A, Takeuchi H, Taback B, et al.: Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 2004; 64: 2245-2250. (Pubitemid 38339479)
78. Miranda TB, Jones PA:, DNA methylation: The nuts and bolts of repression. J Cell Physiol 2007; 213: 384-390. (Pubitemid 47509717)
79. Tanemura A, Terando AM, Sim MS, et al.: CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009; 15: 1801-1807.
80. Nguyen T, Kuo C, Nicholl MB, et al.: Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2010; 6: 388-394.
81. Gal-Yam EN, Saito Y, Egger G, et al.: Cancer epigenetics: Modifications, screening, and therapy. Annu Rev Med 2008; 59: 267-280. (Pubitemid 351287937)
82. Howell PM, Jr., Liu S, Ren S, et al.: Epigenetics in human melanoma. Cancer Control 2009; 16: 200-218.
83. Hoon DS, Spugnardi M, Kuo C, et al.: Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004; 23: 4014-4022. (Pubitemid 38747930)
84. de Maat MF, van de Velde CJ, van der Werff MP, et al.: Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. J Clin Oncol 2008; 26: 2327-2335.
85. Kitago M, Martinez SR, Nakamura T, et al.: Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 2009; 15: 2988-2994.
86. Ito Y:, Oncogenic potential of the RUNX gene family: 'Overview'. Oncogene 2004; 23: 4198-4208. (Pubitemid 38765135)
87. Chuang LS, Ito Y:, RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010; 29: 2605-2615.
88. Chen XQ, Stroun M, Magnenat JL, et al.: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996; 2: 1033-1035. (Pubitemid 26306844)
89. Nawroz H, Koch W, Anker P, et al.: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996; 2: 1035-1037. (Pubitemid 26306845)
90. Yamada T, Nakamori S, Ohzato H, et al.: Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: Correlation with clinicopathological features. Clin Cancer Res 1998; 4: 1527-1532. (Pubitemid 28265239)
91. Taback B, O'Day SJ, Boasberg PD, et al.: Circulating DNA microsatellites: Molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 2004; 96: 152-156. (Pubitemid 38195907)
92. Fujimoto A, O'Day SJ, Taback B, et al.: Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res 2004; 64: 4085-4088. (Pubitemid 38802408)
93. Shinozaki M, O'Day SJ, Kitago M, et al.: Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 2007; 13: 2068-2074. (Pubitemid 46649874)
94. Mori T, Martinez SR, O'Day SJ, et al.: Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 2006; 66: 6692-6698. (Pubitemid 44085626)
95. Mori T, O'Day SJ, Umetani N, et al.: Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005; 23: 9351-9358.